Neural Signals as Language: The Startup Making Brain-Computer Communication a Product, Not a Lab Project

A startup profiled by Tech in Asia is using neural signals to restore communication in people who have lost the ability to speak. The technology—reading motor-neuron firing patterns and converting them to text or speech—is moving from academic demonstration to productized clinical application. The AI layer that makes this possible is less exotic than it sounds.

In plain terms

Some people cannot speak—due to stroke, ALS, or spinal injury. Their thoughts remain intact; the pathway from brain to voice is broken. Brain-computer interfaces aim to read the electrical signals from neurons the person is still firing and convert those signals into words. A startup called Neural Drive is developing this as a product—and claims to have reduced the cost of doing so by 90%.

What Neural Drive is doing

Tech in Asia’s profile outlines Neural Drive with three key claims: it cuts the cost of assistive communication devices by 90%, eliminates the need for surgical implants, and removes the need for complex clinical calibration. If accurate, these three advances address the major barriers to BCI adoption all at once.

Most existing BCI communication systems require either surgical implants (high cost, high risk, limiting the eligible population) or intensive clinical setup—days of calibration sessions with a trained technician. Neural Drive’s approach is non-invasive and designed to minimize calibration to a practical minimum.

The AI layer

The most significant development in BCI communication over the past 18 months is the integration of large language models not as content generators but as signal interpreters. A raw neural decode might produce “I wnt wtr”—the LLM-assisted pipeline outputs “I want water.” The person is generating the intent; the model is simply hearing them more accurately.

This architecture matters for both ethics and engineering: the LLM is not speaking for the person. It is hearing them more clearly. That distinction determines whether this technology restores autonomy or replaces it.

The path to product

Moving from an academic BCI demo to a clinical product involves FDA clearance (for any neural interface device), payer reimbursement pathways, training for clinical staff, and durability data from extended real-world use. Neural Drive’s non-invasive, low-calibration approach potentially simplifies two of these hurdles: regulatory risk for non-implanted devices is lower, and clinical training requirements are reduced.

So what

If validated at scale, Neural Drive’s 90% cost reduction and no-implant approach would expand the addressable population for BCI communication from a narrow surgical candidate pool to a much larger group of people with communication impairments. Watch for clinical trial data in the next 12–18 months—that’s when the real-world performance story becomes clear.